How would you continue management of a patient with clinical stage II cN+ HR+ HER2+IDC with grade 3 diarrhea after 1 cycle of neoadjuvant TCHP?  

Diarrhea is very common with TCHP, with about 70% of patients having diarrhea and 10% having diarrhea grade 3 or higher. Pertuzumab is the primary culprit, although diarrhea is more common when this is combined with chemotherapy. I would assure adequate hydration and replace electrolytes as appropri...

In addition to pertuzumab, it is important to be aware that carboplatin can add to the risk, especially as it's dosed based on AUC not just BSA or body weight. In patients with extremes of weight (falls outside normal distribution curves), the accuracy of carboplatin dosing can be affected and may ...